

Table XXX-1

MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOPROLIFERATIVE DISORDERS, AND CHRONIC MYELOMONOCYTIC LEUKEMIACounts, Percents and Age-Adjusted Incidence Rates^a for the 17 SEER Geographic Areas by Subtype, 2001-2005

Site	Both Sexes			Males			Females		
	Count	Percent	Rate	Count	Percent	Rate	Count	Percent	Rate
Total	22561	100.0%	6.4	12244	100.0%	8.3	10317	100.0%	5.1
Myelodysplastic syndromes (MDS)	13328	100.0%	3.8	7294	100.0%	5.1	6034	100.0%	2.9
Refractory anemia (RA), NOS	2047	15.4%	0.6	1044	14.3%	0.7	1003	16.6%	0.5
RA with ringed sideroblasts	1427	10.7%	0.4	782	10.7%	0.6	645	10.7%	0.3
RA with excess blasts (RAEB)	1814	13.6%	0.5	1102	15.1%	0.7	712	11.8%	0.4
RAEB in transformation	169	1.3%	0.0	96	1.3%	0.1	73	1.2%	0.0
Refractory cytopenia w/multilineage dysplasia	566	4.2%	0.2	354	4.9%	0.2	212	3.5%	0.1
Myelodysplastic syndrome with 5q deletion	220	1.7%	0.1	84	1.2%	0.1	136	2.3%	0.1
Therapy-related myelodysplastic syndrome	229	1.7%	0.1	103	1.4%	0.1	126	2.1%	0.1
Myelodysplastic syndrome, NOS	6856	51.4%	1.9	3729	51.1%	2.6	3127	51.8%	1.5
Chronic myeloproliferative disorders (CMD)	7937	100.0%	2.2	4175	100.0%	2.6	3762	100.0%	1.9
Polycythemia vera	3307	41.7%	0.9	1929	46.2%	1.2	1378	36.6%	0.7
Chronic myeloproliferative disease, NOS	1466	18.5%	0.4	779	18.7%	0.5	687	18.3%	0.3
Myelosclerosis with myeloid metaplasia	876	11.0%	0.2	511	12.2%	0.3	365	9.7%	0.2
Essential thrombocythemia	2136	26.9%	0.6	869	20.8%	0.6	1267	33.7%	0.6
Chronic neutrophilic leukemia	16	0.2%	0.0	-	-	-	-	-	-
Hypereosinophilic syndrome	136	1.7%	0.0	78	1.9%	0.0	58	1.5%	0.0
Chronic myelomonocytic leukemia (CMML)	1296	100.0%	0.4	775	100.0%	0.5	521	100.0%	0.3

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

- Statistic not shown due to fewer than 16 cases during the time period.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).